HypertensionPhase 3GMRx2_ACTNCT04518293
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
A Phase 3 study testing Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg and Telmisartan 20 mg/amlodipine 2.5 mg in people with Hypertension, run by George Medicines PTY Limited at 89 sites in 7 countries.
Trial summary
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure (BP) control without increasing adverse effects. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension
- What is being tested?
- Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg and Telmisartan 20 mg/amlodipine 2.5 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,385 participants
- Where
- 89 sitesin 7 countries
- Study dates
- 9 Jul 2021to 1 Sep 2023
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- At screening visit
- Provided signed consent to participate in the trial.
- Adult of age ≥18 years.
- Attended automated clinic seated mean systolic blood pressure (SBP) (average of last 2 measurements calculated by the device):
- 140-179 mmHg on 0 BP-lowering drugs, or 130-170 mmHg on 1 BP-lowering drug, or 120-160 mmHg on 2 BP-lowering drugs, or 110-150 mmHg on 3 BP-lowering drugs.
- At randomization visit
Show all 10Show fewer
- Home seated mean SBP 110-154 mmHg in the week prior to the randomization visit.
- Adherence of 80-120% to run-in medication.
- Tolerated run-in medication.
- Adherence to home BP monitoring schedule: in the week before randomization, at least 6 measures (e.g. ≥2 sets of triplicate measures, ≥3 sets of duplicate measures) including at least 1 morning and 1 evening each with ≥2 measures. Morning is defined as any measure in the am and evening as any measure in the pm. Morning and evening do not have to be same day.
Who cannot join
- At screening visit
- Receiving 4 or more BP-lowering drugs.
- Receiving any BP lowering drugs for indications other than hypertension e.g. heart failure
- Pregnant or had a positive pregnancy test or unwilling to undertake a pregnancy test during the trial and up to 30 days after the discontinuation of the trial medication or breastfeeding or of childbearing age and not using an acceptable method of contraception. Acceptable methods of birth control include hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), or male partner sterilization. Contraception should be used for at least 1 month before the screening visit and until the end of trial participation.
- Not suitable for participation in a clinical trial according to local ethical or regulatory requirements related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
- Contraindication, including hypersensitivity (e.g. anaphylaxis or angioedema), to the active run-in treatment or to any of the trial medication options in the four randomized groups.
Show all 30Show fewer
- Current/history of transient ischemic attack, stroke, or hypertensive encephalopathy.
- Current/history of acute coronary syndrome, unstable angina, myocardial infarction, percutaneous transluminal coronary revascularization, or coronary artery bypass graft.
- Current atrial fibrillation. Patients with a history of paroxysmal atrial fibrillation are potentially eligible as long as there has been no episode in the last 3 months, while patient with a history of persistent or permanent atrial fibrillation are not eligible.
- Current/history of New York Heart Association class III and IV congestive heart failure.
- Current/history of a known secondary cause of hypertension, such as primary aldosteronism, renal artery stenosis, pheochromocytoma, or Cushing's syndrome.
- Current/history of substantially uncontrolled diabetes (HbA1c > 11.0%) within last three months.
- Current/history of end-stage renal disease or anuria or estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2.
- Electrolyte levels that would be regarded as contraindications for any of the potential treatment arms e.g. serum sodium <132mmol/l or >148mmol/l serum potassium <3.1 mmol/l or >5.6 mmol/l.
- Current/history of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal range within 6 months.
- Current concomitant illness or physical impairment or mental condition that in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
- Arm circumference that is too large (>55 cm) or too small (<15-24 cm) to allow accurate measurement of BP.
- Currently taking or might need during the trial, a concomitant treatment which is known to interact with one or more of the trial medications: digoxin, lithium, diabetics receiving aliskiren, moderate and strong CYP3A4 inhibitors (e.g. ritonavir, ketoconazole, diltiazem], simvastatin >20 mg/day, immunosuppressants.
- Might need treatment with drugs that are prohibited during the trial: other antihypertensive drugs, endothelin receptor antagonists, neprilysin inhibitors, or other drugs that may affect BP.
- Current surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of trial drugs such as prior major gastrointestinal tract surgery (e.g. gastrectomy, lap band, or bowel resection) or acute flare of inflammatory bowel disease within one year.
- Individuals working >2 nightshifts per week.
- Participated in any investigative drug or device trial within the previous 30 days.
- History of alcohol or drug abuse within 12 months.
- At randomization visit
- Unable to adhere to the trial procedures during the run-in treatment period.
- Any of the following which in the investigator's judgment may compromise the safety of the participant if randomized to the trial medications:
- High or low clinic BP levels even in the light of the values for home BP that are available for that participant. The exact levels of BP are not specified, since there is clinical uncertainty as to the relevance of BP levels which are high or low in clinic only; for example, the clinical relevance of 'whitecoat hypertension' is uncertain.
- High or low home diastolic BP (DBP) levels. The exact levels of DBP is not specified, reflecting clinical uncertainty of the implications of isolated diastolic hypertension. However, home DBP values of >99 mmHg may typically be considered as requiring treatment intensification, and such participants would not be suitable for randomization.
- Any abnormal laboratory value which in the judgment of the investigator could interfere with the effective conduct of the trial or constitutes a significant risk to the participants' well-being.
- Fulfilling any of the exclusion criteria mentioned for the screening visit, when verified again at randomization visit.
Trial locations and contacts
89 sites in 7 countries.
89 sites in 7 countries
United States31 sites
ACRC Trials - Southwest Medical Village
Austin, Texas, 78735
ACRC Trials - Premier Family Physicians
Austin, Texas, 78746
Meridian Clinical Research
Baton Rouge, Louisiana, 70809
Clinical Research of Brandon
Brandon, Florida, 33511
ACRC Trials - Family Medicine Associates of Texas
Carlton, Texas, 75010
Javarra Research
Charlotte, North Carolina, 28210
Meridian Clinical Research
Endwell, New York, 13760
East Carolina University
Greenville, North Carolina, 27834
Inpatient Research Clinic
Hialeah, Florida, 33013
Synergy Groups Medical
Houston, Texas, 77036
Synergy Groups Medical
Houston, Texas, 77087
Multi-Speciality Research Associates
Lake City, Florida, 32055
Loyola University
Maywood, Illinois, 60153
The University of Tennessee Health Science Center
Memphis, Tennessee, 38105
Suncoast Research Group
Miami, Florida, 33135
New Horizon Research Center
Miami, Florida, 33165
Synergy Groups Medical
Missouri City, Texas, 77459
North Hills Medical Research
North Richland Hills, Texas, 76180
Ocala Research Institute
Ocala, Florida, 34471
Elite Clinical Studies
Phoenix, Arizona, 85018
ACRC Trials - Village Health Partners
Plano, Texas, 75093
Meridian Clinical Research
Portsmouth, Virginia, 23703
Meridian Clinical Research
Savannah, Georgia, 31406
Headlands Research
Scottsdale, Arizona, 85260
Buckhead Primary Care Research
Snellville, Georgia, 30078
Valiance Clinical Research
South Gate, California, 90280
Suncoast Research Associates
St. Petersburg, Florida, 33173
Accel Research
St. Petersburg, Florida, 33709
Precision Research Center
Tampa, Florida, 33603
Valiance Clinical Research
Tarzana, California, 91356
Quality of Life Medical & Research Associates
Tucson, Arizona, 85712
United Kingdom25 sites
Atherstone Surgery
Atherstone, Warwickshire, CV9 1EU
Heart of bath Medical Partnership
Bath, Somerset, BA2 3HT
Layton Medical Centre
Blackpool, Lancashire, FY3 7EN
Waterloo Medical Centre
Blackpool, Lancashire, FY4 3AD
West Walk Surgery
Bristol, Somerset, BS37 4AX
Ely Bridge
Cardiff, Wales, CV32 4RA
Royal Primary care Ashgate
Chesterfield, Derbyshire, S40 4AA
Hathaway Surgery
Chippenham, Wiltshire, SN14 6GT
Rowden Surgery
Chippenham, Wiltshire, SN15 2SB
Lakeside Surgery
Coventry, West Midlands, CV3 6NF
Carmel Medical Practice
Darlington, Durham, DL3 8SQ
Belmont Health Centre
Harrow, London, HA3 7LT
Burbage Surgery
Hinckley, Leicestershire, LE10 2SE
Portmill Surgery
Hitchin, Herts., SG49TH
PRC Leciester
Leicester, East Midlands, LE5 4PW
Bart's NHS Trust
London, EC1M6BO
Tyntesfield Medical Group
Nailsea, Somerset, BS48 1BZ
Newquay Medical
Newquay, Cornwall, TR7 1RU
Clifton Medical centre
Rotherham, South Yorkshire, S65 1DA
Sherbourne Medical Centre
Royal Leamington Spa, West Midlands, CV324RA
Ashfields Primary Care Centre
Sandbach, Cheshire, CW11 1EQ
Ecclesfield group Practice
Sheffield, S35 9XQ
Steploe Medical Centre
Soham, Cambridgeshire, CB7 5JD
Trowbridge Health Centre
Trowbridge, Wiltshire, BA14 8LW
The Adam Practice
Upton, Poole, BH165PW
Poland12 sites
Medical University of Gdansk
Gdansk, Gdansk, 80-214
Medical University of Gdansk
Gdansk
Pratia Katowice Medical Centre
Katowice, 40-081
Pratia Katowice Medical Centre
Katowice
Nowodworskie Medical Center
Nowy Dwór Mazowiecki
Medical Center Pratia Poznan
Poznan
ETG Network
Skierniewice, 96-100
ETG Network
Skierniewice
The Medical University of Warsaw
Warsaw
Futuremeds
Wroclaw, Wroclaw, 50-088
EMC Instytut Medyczny S.A
Wroclaw
Futuremeds
Wroclaw
Sri Lanka10 sites
Clinical Medicine Academic & Research Centre
Colombo, 10-01000
Institute of Cardiology, National Hospital of Sri Lanka
Colombo, 10-01000
Colombo South Teaching Hospital
Dehiwala, 10350
Karapitiya Teaching Hospital
Galle, 80000
Jafna Teaching Hospital
Jaffna, 40000
Kandy National Hospital
Kandy, 20000
Kurunegala Teaching Hospital
Kurunegala, 60000
Negombo District General Hospital
Negombo, 11500
Sri Jayawardenapura General Hospital
Nugegoda, 10250
Colombo North Teaching Hospital
Ragama, 11010
Australia6 sites
Curtin University
Bentley, Western Australia, 6102
Princess Alexandra Hospital - Hypertension Unit
Brisbane, Queensland, 4102
Castle Hill Medical Centre
Castle Hill, New South Wales, 2154
Hudson Institute of Medical Research
Clayton, Victoria, 3168
Barwon Health, Geelong University Hospital
Geelong, Victoria, 3220
Royal Perth Hospital
Perth, Western Australia, 6000
Czechia3 sites
Private Cardiologic Ambulance, Medicus Services s.r.o
Brandýs nad Labem, Central Bohemia, 250 01
EDUMED, s.r.o
Broumov, Kralovehradsky, 550 01
EDUMED, s.r.o
Jaroměř, Kralovehradsky, 551 01
New Zealand2 sites
Gisborne Hospital
Gisborne, 4040
Middlemore Clinical Trials
Otahuhu, Auckland, 2025
About this study
Official title: Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Dual Combinations for the Treatment of Hypertension
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure (BP) control without increasing adverse effects. This trial is designed to investigate the efficacy and safety of GMRx2 in participants with high blood pressure compared to dual combinations.
Read the detailed description
TRIAL DRUG:
GMRx2: Single pill combinations of telmisartan/amlodipine/indapamide Dose version 2: telmisartan 20mg/amlodipine 2.5mg/indapamide 1.25mg Dose version 3: telmisartan 40mg/amlodipine 5 mg/indapamide 2.5mg INDICATION: Hypertension TRIAL DESIGN: International, multicenter, randomized, double-blind, active controlled, parallel-group.
OBJECTIVES: To investigate the efficacy and safety of GMRx2 compared to dual combinations
INTERVENTION:
Single-Blind Active Run-In Period. Enrolled participants will be asked to discontinue their current BP-lowering drug(s) and undergo a single-blind active run-in period for 4 weeks with GMRx2 dose version 2. Participants will be advised to take the capsule once daily in the morning at approximately the same time each day. For days on which BP is being measured, the capsule should be taken directly after the morning home BP measurement.
Double-Blind Treatment Period. Participants still eligible after the run-in period will be allocated in a double-blind fashion to one of the following 4 randomized groups: GMRx2 dose version 2, or telmisartan 20mg+amlodipine2.5mg, or telmisartan 20mg+indapamide 1.25mg, or amlodipine 2.5mg+indapamide 1.25mg. At week 6 all doses will be doubled.
- Conditions
- Hypertension
- Being tested
- Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg, telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mgDrug
Single pill
telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mgDrug
Single pill
Telmisartan 20 mg/amlodipine 2.5 mgDrug
oral tablet
telmisartan 40 mg/amlodipine 5 mgDrug
oral tablet
Telmisartan 20 mg/indapamide 1.25 mgDrug
oral tablet
telmisartan 40 mg/indapamide 2.5 mgDrug
oral tablet
Amlodipine 2.5 mg/indapamide 1.25 mgDrug
oral tablet
amlodipine 5 mg/indapamide 2.5 mgDrug
oral tablet
| Study group | Role | What they receive |
|---|---|---|
| GMRx2 | Experimental | Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg Receives: Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg; Drug: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg |
| Dual - TA | Active comparator | Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg Receives: Drug: Telmisartan 20 mg/amlodipine 2.5 mg; Drug: telmisartan 40 mg/amlodipine 5 mg |
| Dual - TI | Active comparator | Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg Receives: Drug: Telmisartan 20 mg/indapamide 1.25 mg; Drug: telmisartan 40 mg/indapamide 2.5 mg |
| Dual - AI | Active comparator | Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg Receives: Drug: Amlodipine 2.5 mg/indapamide 1.25 mg; Drug: amlodipine 5 mg/indapamide 2.5 mg |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
The primary outcome measure is difference in change in average home SBP for GMRx2 vs each dual combination evaluated from randomization to Week 12. The change in home SBP from randomization for all treatment arms was measured using least squares (LS) mean change. The pairwise comparisons between GMRx2 and dual treatments in change in home SBP were estimated using LS means difference and are described in the statistical analysis.
Measured: Week 12
Secondary outcomes (17)
Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
Measured: Week 12
Difference in Change in Clinic Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
Difference in change in average clinic SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
Measured: Week 6
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12
Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
Measured: Week 12
Difference in Change in Clinic Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6
Difference in change in average clinic DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
Measured: Week 6
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 12
The percentage of participants achieving averaged clinic SBP <140 mmHg and DBP <90 mmHg at Week 12 was evaluated.
Measured: Week 12
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <140 and Diastolic Blood Pressure (DBP) <90 mmHg at Week 6
The percentage of participants achieving averaged clinic SBP <140 mmHg and DBP <80 mmHg at Week 6 was evaluated.
Measured: Week 6
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12
The percentage of participants achieving averaged clinic SBP <130 mmHg and DBP <80 mmHg at Week 12 was evaluated.
Measured: Week 12
Percentage of Participants With Clinic Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6
The percentage of participants achieving averaged clinic SBP <130 mmHg and DBP <80 mmHg at Week 6 was evaluated.
Measured: Week 6
Difference in Change in Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
Difference in change in average home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
Measured: Week 6
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 12
Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12.
Measured: Week 12
Difference in Change in Home Seated Mean Diastolic Blood Pressure (DBP) From Randomization to Week 6
Difference in change in average home DBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6.
Measured: Week 6
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 12
Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 12. Trough values were measured before morning dose of the study medication.
Measured: Week 12
Difference in Change in Trough Home Seated Mean Systolic Blood Pressure (SBP) From Randomization to Week 6
Difference in change in trough home SBP for GMRx2 vs each dual combination was evaluated from randomization to Week 6. Trough values were measured before morning dose of the study medication.
Measured: Week 6
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 12
The percentage of participants achieving averaged home SBP <135 mmHg and DBP <85 mmHg at week 12 was calculated.
Measured: Week 12
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <135 and Diastolic Blood Pressure (DBP) <85 mmHg at Week 6
The percentage of participants achieving averaged home SBP <135 mmHg and DBP <85 mmHg at Week 6 was evaluated.
Measured: Week 6
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 12
The percentage of participants achieving averaged home SBP <130 mmHg and DBP <80 mmHg at Week 12 was evaluated.
Measured: Week 12
Percentage of Participants With Home Seated Mean Systolic Blood Pressure (SBP) <130 and Diastolic Blood Pressure (DBP) <80 mmHg at Week 6
The percentage of participants achieving averaged home SBP <130 mmHg and DBP <80 mmHg at Week 6 was evaluated.
Measured: Week 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2020
- Study start9 Jul 2021
- Primary completion11 Aug 2023
- Study completion1 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- International, multicenter, randomized, double-blind, active-controlled, parallel group.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,385 participants (actual)
Sponsor and investigators
- Lead sponsor
- George Medicines PTY Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Anthony Rodgers, Professor, Principal investigator, The George Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04518293
- Sponsor's protocol ID
- GMRx2-HTN-2020-ACT1
- Acronym
- GMRx2_ACT
- Status last verified
- Apr 2025
- First submitted
- 15 Aug 2020
- Last updated
- 3 Jun 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: If the sponsor receives a request for study data, then such requests will be reviewed by sponsor following completion of regulatory submissions and review, and with support from members of the GMRX2 steering committee who will advise on the scientific merit and integrity of the proposed analysis.
Publications
Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, Grobbee DE, Narkiewicz K, Ojji DB, Poulter NR, Schlaich MP, Oparil S, Spiering W, Williams B, Wright JT Jr, Lakshman P, Uluwattage W, Hay P, Pereira T, Amarasena N, Ranasinghe G, Gianacas C, Shanthakumar M, Liu X, Wang N, Gnanenthiran SR, Whelton PK; GMRx2 Investigators. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024 Oct 19;404(10462):1536-1546. doi: 10.1016/S0140-6736(24)01744-6.
PubMed 39426836